

Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics

VIRTUAL EXAM ROOM RESOURCE GUIDE

RECENT GUIDELINE RECOMMENDATIONS FOR SEVERE ASTHMA

[2022 GINA Report, Global Strategy for Asthma Management and Prevention](#)

CLINICAL TRIALS

Approved Agents

[Tezepelumab in Adults with Uncontrolled Asthma \(PATHWAY Trial\)](#)

[Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma \(NAVIGATOR Trial\)](#)

Investigational Agents

[Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma](#)

[Astegolimab \(anti-ST2\) Efficacy and Safety in Adults With Severe Asthma: A Randomized Clinical Trial](#)

REAL-WORLD TRIALS AND SEVERE ASTHMA REGISTRIES

[CHRONICLE Study](#)

[The International Severe Asthma Registry](#)

OPTIMIZING PATIENT TREATMENT & OUTCOMES

[Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study](#)

[The Airway Epithelium—A Central Player in Asthma Pathogenesis](#)

[Airway Hyperresponsiveness in Asthma: Its Measurement and Clinical Significance](#)

ROLE OF EPITHELIAL ALARMINS IN SEVERE ASTHMA

Click image to view animation

